Quanterix Corp. (QTRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$2.65-2.93%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Gross margin improves to about 51% in FY26: FY26 GM guidance 49.0% vs ~51% target; Q2 actual 38.5% vs 45% trip.
Quanterix is improving its leadership with new CFO and COO hires. Revenue is expected to grow about 19% in 2026 to $171.5 million. Gross margin should improve to about 51% by year-end. The company is working to stabilize after recent losses.
Quanterix remains unprofitable with negative free cash flow. Revenue declined from $43.9M in 2025-Q4 to $36.4M in 2026-Q1. Earnings continue to miss estimates. Management changes add uncertainty.
The market prices in about 19% revenue growth in 2026 and expects losses to continue. Our fair value near $14.39 reflects this cautious outlook. The stock trades at a discount to peers but with high risk.
Breaks if: Gross margin falls below 45% in FY26
Breaks if: Additional unexpected departures of CFO or COO
Breaks if: Revenue falls below $130 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving commercial effectiveness and achieving cash flow breakeven by 2027. The current thesis is mixed, as recent financial performance has been weak, but management is actively addressing challenges.
The market seems to have priced in a low expectations gap, indicating that investors are not anticipating significant improvements in performance. Valuation appears cheap compared to peers, but with a premium that suggests some cautious optimism.
Fundamentals may improve if management successfully drives commercial effectiveness and addresses margin pressures. However, there are risks, particularly if broader economic conditions worsen, which could impact performance.
The long-term thesis hinges on management's ability to raise guidance in the next quarter and improve financial performance. Additionally, the performance of sector bellwethers and overall economic conditions will be critical factors to monitor.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company aims to drive commercial effectiveness and improve operating results. This sales reset could enhance its growth trajectory. There are no new threats identified at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Drive revenue growth through strategic initiatives and market expansion.
In the next 1 to 3 years, QTRX's trajectory will depend on management execution and external economic factors. Not investment advice.